Ronin Trading, SW Investment Management nominate James Egan to Peregrine Pharmaceuticals Board
Oct 10 (Reuters) - Ronin Trading, LLC and SW Investment Management LLC::Ronin Trading and SW Investment Management announce additional nomination to Board of Peregrine Pharmaceuticals.Ronin Trading and SW Investment Management - nomination of James (Jamie) J. Egan, for election to Peregrine's Board at co's 2017 annual meeting.Ronin Trading and SW Investment Management say collectively have beneficial ownership of about 8.9% of Peregrine's outstanding shares of common stock.
Latest Key Developments inPharmaceuticals
- Pfizer's Lyrica Fails to Meet Main Goal in Late-stage Epilepsy Study
- Avexis Says Annualized Cost Of Zolgensma Is USD 425,000 Per Year For 5 Years
- Eve & Co Reports Quarterly Results
- Theratechnologies - European Medicine Agency Grants Theratechnologies An Additional Month To Complete Responses Related To Trogarzo Application